Molecular Therapeutics
VIDEO: Intravitreally administered 4D-150 shows 90% reduction in wet AMD treatment burden
BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Anat Loewenstein, MD, MHA, speaks about 4D-150, a novel intravitreally administered gene therapy for wet age-related macular degeneration.
VIDEO: Safety data encouraging for 4D-150 in patients with wet AMD
In this video, Donald J. D’Amico, MD, discusses data from the phase 1/2 PRISM trial of 4D-150 in patients with neovascular age-related macular degeneration.
VIDEO: 4D Molecular Therapeutics shares update on retinal disease candidates
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, David Kirn, MD, of 4D Molecular Therapeutics provides an update on two candidates for retinal diseases.
VIDEO: ‘Excellent’ anatomic, vision control seen with 4D-150 at 24 weeks
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Carl Danzig, MD, discusses a subset analysis of high-need patients receiving 4D-150 for wet age-related macular degeneration in the PRISM trial.
VIDEO: 4D-150 shows positive interim results in phase 2 trial for severe wet AMD
In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Arshad M. Khanani, MD, MA, FASRS, overviews phase 2 efficacy and safety data for 4D-150 for the treatment of neovascular age-related macular degeneration.
4D Molecular Therapeutics completes enrollment in expansion stage of phase 2 wet AMD trial
4D Molecular Therapeutics completed enrollment in the phase 2 dose expansion stage of the PRISM clinical trial investigating 4D-150 for wet age-related macular degeneration, according to a press release.
Astellas, 4D Molecular Therapeutics enter license agreement for retinotopic vector
Astellas Pharma and 4D Molecular Therapeutics have entered into a license agreement that grants Astellas the rights to utilize 4DMT’s intravitreal retinotopic R100 vector for treating rare monogenic ophthalmic diseases.